The purity of reagents directly impacts the reliability of experimental outcomes
In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Biotechnology company Sino Biological’s recent launch of ProPure, an advanced line of endotoxin-free recombinant proteins. aims to address this need.
What Are ProPure Endotoxin-Free Proteins?
ProPure represents a new industry standard in the manufacture of recombinant proteins with ultra-low endotoxin content. Unlike conventional preparations, ProPure products are engineered to achieve endotoxin levels below the limit of quantification (LOQ). They are entirely produced in the US at Sino Biological’s centre for bioprocessing (C4B) in Houston, Texas. This facility leverages mammalian expression systems and proprietary multi-step purification protocols to deliver proteins with exceptional purity, stability, and biological integrity.
Endotoxin contamination can derail sensitive experiments and therapeutic applications in the following ways:
- Distorted data: Even low levels of endotoxin can activate immune pathways, leading to false signals in cell-based assays and immunological studies.
- Safety concerns: Contaminated proteins used for animal studies or clinical research may induce harmful inflammatory reactions, endangering animal welfare or patient safety.
- Regulatory compliance: Biomanufacturing and therapeutic protein production require strict endotoxin control to meet regulatory standards and ensure product safety. Features and advantages of ProPure:
- Ultra-low endotoxin content: Advanced purification techniques ensure endotoxin levels below the limit of quantification (LOQ), surpassing industry requirements and minimising experimental risk.
- Mammalian expression systems: These systems, paired with tailored protocols, minimise bacterial endotoxin introduction and yield proteins with native-like post-translational modifications (PTMs), folding, and functionality.
- High consistency and quality: The proprietary manufacturing process ensures batch-to-batch consistency, essential for reproducible results in sensitive applications such as immunology, vaccine research, and animal studies.
- Customisation options: In addition to standard catalog proteins, ProPure provides made-to-order custom protein development to serve unique research and production requirements.
- Made in the US: The US-based C4B facility underscores Sino Biological’s commitment to supporting the worldwide life sciences community with rapid production, reliable logistics, and robust quality assurance.
Customer-centric innovation
Sino Biological’s philosophy goes beyond shipping ultra-pure proteins. The C4B also partners with research labs and biotech firms to offer:
- Custom protein production: Tailored to meet specific research needs, including production scale, tag design, and formulation.
- Fast turnaround: The integration of cutting-edge technologies, strong expertise in recombinant production, and rapid shipping leads to shorter lead times and increased reliability, crucial during urgent projects like pandemic response or immunotherapy development.
- Technical Support: Expert consultation and technical guidance improve experimental success.
The benefits of C4B for Endotoxin-free protein production?
- Optimised mammalian expression platforms and rigorous QC ensure high quality and consistency
- Customised proteins and antibodies with an approximate two week delivery window.
- 24 well plates to 25 L bioreactors for your screening to production level protein needs
- Advanced equipment and minimal endotoxin during processing
Impact and industry recognition
Sino Biological argues that ProPure marks a new life sciences benchmark for the following reasons:
- Researchers and biomanufacturers have a trustworthy source for recombinant proteins, enhancing accuracy, reproducibility, and safety.
- The launch of the ProPure product line marks Sino Biological’s ongoing investment in both technological innovation and service to the global scientific community.
Conclusion
In today’s landscape of advanced biomedical research and therapeutics, using endotoxin-free proteins has never been more important. Sino Biological’s endotoxin-free recombinant proteins mean researchers and industry professionals can perform at a high standard, bolstering scientific excellence while minimising risk, according to the company. As research becomes ever more sophisticated and regulatory requirements tighten, the innovation heralds a new era of safety, consistency, and scientific integrity for life science applications.
ProPure delivers below LOQ endotoxin levels:
Sino Biological’s ProPure prduct benefits from minimum endotoxin levels during protein production
- Endotoxin-free plasmids
- Endotoxin-free buffer with filtration
- Low endotoxin-affinity plastic containers
- Regular clean-in-place (CIP)
An example Protein
A strong example of endotoxin-free protein quality is the Human B7-H3/CD276 protein, which achieves over 90% purity by SDS-PAGE and SEC-HPLC. Its purity and correct molecular size (about 60.4 kDa by SEC-MALS) are confirmed, while its bioactivity is verified by ELISA with an EC50 of 6.7 ng/mL. This case underscores the importance of rigorous testing for purity, identity, and bioactivity to guarantee high-quality, contamination-free proteins for sensitive research.
